

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Taltz (Ixekizumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:		Prescriber Name: Supervising Physicia	n·	
Member/Subscriber Numb	ei.	Fax: Office Contact:	Phone:	
Date of Birth: Group Number:		NPI:	State Lic ID:	
Address:		Address:	State Lit ID.	
City, State ZIP:		City, State ZIP:		
Primary Phone:		Specialty/facility name	(if applicable):	
——————————————————————————————————————		Эресіануласііну паше	(п аррпсавіе).	
Drug Name and Strength:				
Directions / SIG:				
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.				
Q1. What diagnosis is	this drug being prescribed	for (pick one)?		
☐ Plaque Psoriasis	☐ Other	,		
Q2. Please provide IC	D code for diagnosis.			
	Ü			
Q3. Is the prescriber a	Dermatologist?			
☐Yes	☐ No			
Q4. Does the patient h	nave moderate to severe pla	aque psoriasis affecting greater	than 10% of body surface area	
☐Yes	☐ No			
Q5. Does the patient h or genitals?	nave moderate to severe pla	aque psoriasis affecting crucial	body areas such as hands, feet, face,	
Yes	☐ No			
1		treatments [including but not linbinations, Tazorac® (tazarote	mited to corticosteroids, Vitamin D	
Yes	☐ No			



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Taltz (Ixekizumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

	Prescriber Name:			
Patient Name:	Supervising Physician:			
Q7. Has the patient failed or does the patient have a contraindication to phototherapy (UVB or PUVA)?				
☐ Yes ☐ No				
Q8. Has the patient failed or does the patient have a contraindication to methotrexate, cyclosporine, acitretin, leflunomide, sulfasalazine, OR tacrolimus?				
☐ Yes ☐ No				
Q9. Please select all of the following agents that the patient Humira Enbrel Cosentyx Remicade Stelara Other	t has failed, has an intolerance or contraindication to:			
Pharmacy claim (drug to be billed as a PHARMACY be to this specific member)	enefit claim and dispensed by pharmacy directly to member) enefit claim, but shipped direct to provider to be administered MEDICAL benefit claim as an expense to the provider, and			
Q11. If billing as a MEDICAL claim, what provider will be lift reimbursement)? Provide Name and NPI Individual prescriber Provider or specialty group Facility	nked to the claim (i.e. who is the billing entity seeking			
Q12. Additional comments				



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Taltz (Ixekizumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

	Prescriber Name:	
Patient Name:	Supervising Physician:	
Prescriber Signature	Date	
□ Expedited/Urgent - By checking this box and signing abov seriously jeopardize the life or health of the enrollee or the e		

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to a SWHP pharmacist or medical director at 1-800-728-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document